Preoperative Levosimendan in CABG Patients With Poor LV Function

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cardiacsurgeryventricularfractionleft
  Phrases that lowered it: signedrandomised40scheduledin patients
• Sponsor's past termination rate: 19.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 165 (lowers risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 8.8% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 14340 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 63137 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 66.3% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 312 (lowers risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass NCT02025621 · started 2014 · scored riskier than 92% of active trials completed
• Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction NCT06784570 · started 2021 · scored riskier than 22% of active trials completed
• Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF NCT04560309 · started 2021 · scored riskier than 52% of active trials completed
• Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients NCT04329624 · started 2020 · scored riskier than 75% of active trials completed
• Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries NCT03557255 · started 2017 · scored riskier than 32% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.